Swedish Orphan Biovitrum has filed a patent for an injectable pharmaceutical formulation containing a fully human anti-IFN alpha monoclonal antibody. The formulation includes specific amino acid sequences and excipients, aiming to treat conditions associated with elevated IFN-alpha levels. GlobalData’s report on Swedish Orphan Biovitrum gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Swedish Orphan Biovitrum AB - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Swedish Orphan Biovitrum, Telomerase reverse transcriptase screening was a key innovation area identified from patents. Swedish Orphan Biovitrum's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Pharmaceutical formulation for treating elevated ifn-alpha levels

Source: United States Patent and Trademark Office (USPTO). Credit: Swedish Orphan Biovitrum AB

The patent application (Publication Number: US20240010719A1) discloses an injectable pharmaceutical formulation containing a fully human anti-interferon gamma (IFN-alpha) monoclonal antibody at a concentration of 25 mg/mL. The formulation also includes specific amounts of L-histidine, L-histidine monohydrochloride, Polysorbate 80, and sodium chloride, with a pH range of 5.8 to 6.2. The antibody in the formulation has defined amino acid sequences for variable heavy and light chain complementarity determining regions, making it suitable for treating conditions like primary and secondary hemophagocytic lymphohistiocytosis (HLH) in both pediatric and adult patients.

Furthermore, the patent application describes a unit dose vial containing the fully human anti-IFN alpha monoclonal antibody solution in volumes of 2 mL, 4 mL, 10 mL, or 20 mL. The solution composition and pH range remain consistent with the injectable formulation, ensuring clarity, colorlessness, and absence of precipitates. The method of treating HLH conditions in human subjects using this unit dose vial involves administering the antibody solution, which aligns with the specific amino acid sequences outlined for the antibody's variable heavy and light chain regions. This patent application provides a detailed and specific formulation for an injectable pharmaceutical product aimed at effectively treating HLH conditions in both pediatric and adult patients.

To know more about GlobalData’s detailed insights on Swedish Orphan Biovitrum, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies